Targeting innovation in antibiotic drug discovery ... Targeting innovation in antibiotic drug discovery

  • View
    0

  • Download
    0

Embed Size (px)

Text of Targeting innovation in antibiotic drug discovery ... Targeting innovation in antibiotic drug...

  • Targeting innovation in antibiotic drug discovery and development

    The need for a One Health – One Europe – One World Framework

    Matthew J Renwick, Victoria Simpkin and Elias Mossialos

    A very thorough analysis of the different initiatives to stimulate research and innovation of antibiotics

    Edith Schippers, Minister of Health, Welfare and Sport, The Netherlands

  • Targeting innovation in

    antibiotic drug discovery and development

    The need for a One Health – One Europe – One World Framework

  • The European Observatory on Health Systems and Policies supports and promotes evidence-based health policy-making through comprehensive and rigorous analysis of health systems in Europe. It brings together a wide range of policy-makers, academics and practitioners to analyse trends in health reform, drawing on experience from across Europe to illuminate policy issues.

    The Observatory is a partnership hosted by the WHO Regional Office for Europe; which includes the Governments of Austria, Belgium, Finland, Ireland, Norway, Slovenia, Sweden, the United Kingdom and the Veneto Region of Italy; the European Commission; the World Bank; UNCAM (French National Union of Health Insurance Funds); the London School of Economics and Political Science; and the London School of Hygiene & Tropical Medicine. The Observatory has a secretariat in Brussels and it has hubs in London (at LSE and LSHTM) and at the Technical University of Berlin.

    HEALTH POLICY SERIES

    Study Number 45

  • Targeting innovation in

    antibiotic drug discovery and development

    The need for a One Health – One Europe – One World Framework

    Matthew J Renwick1, Victoria Simpkin1 and Elias Mossialos1,2

    1LSE Health, Department of Social Policy, London School of Economics

    and Political Science, London, United Kingdom

    2European Observatory on Health Systems and Policies,

    London, United Kingdom

  • Keywords aNti-Bacterial aGeNtS DrUG reSiStaNce, MicroBial DrUG DiScoVery DrUG iNDUStry BioMeDical reSearcH

    © World Health organization 2016 (acting as the host organization for, and secretariat of, the european observatory on Health Systems and Policies)

    all rights reserved. the european observatory on Health Systems and Policies welcomes requests for permission to reproduce or translate its publications, in part or in full.

    the designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the european observatory on Health Systems and Policies concerning the legal status of any country, territory, city or area or of its authorities, or concern- ing the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

    the mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the european observatory on Health Systems and Policies in preference to others of a similar nature that are not mentioned. errors and omissions excepted, the names of propri- etary products are distinguished by initial capital letters.

    all reasonable precautions have been taken by the european observatory on Health Systems and Policies to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. the responsibility for the interpre- tation and use of the material lies with the reader. in no event shall the european observatory on Health Systems and Policies be liable for damages arising from its use. the views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the european observatory on Health Systems and Policies or any of its partners.

    ISBN 978 92 890 5040 1

    Printed in the United Kingdom Design by Sarah Moncrieff

    address requests about publications to: Publications, WHo regional office for europe, UN city, Marmorvej 51, DK-2100 copenhagen Ø, Denmark.

    alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the regional office web site (www.euro.who.int/pubrequest).

    http://www.euro.who.int/pubrequest

  • Contents

    Foreword vii

    acknowledgments viii

    executive Summary 1

    list of abbreviations 4

    list of figures and tables 7

    1. objectives 9

    2. Background 11

    2.1 combating the rise of antimicrobial resistance 11

    2.2 the lagging antibiotic development pipeline 13

    2.3 Barriers within the antibiotic development value chain 16

    2.4 incentives to spark innovation in the antibiotics market 21

    2.5 Funding landscape for the development of antibiotics 22

    3. research Methodology 27

    3.1 literature review 27

    3.2 expert input 27

    3.4 Framework for initiative analysis and discussion 29

    4. results 31

    4.1 Key international initiatives that foster r&D of antibiotics 31

    4.2 Key eU initiatives that foster r&D of antibiotics 36

    4.3 Key national initiatives that foster r&D of antibiotics 41

  • 5. Discussion 53

    5.1 How do the current initiatives measure across the evaluation criteria? 53

    5.2 What is the current balance between push and pull incentives? 55

    5.3 What are our knowledge gaps in the global antibiotics market? 58

    5.4 What is the current level of coordination between and within initiatives? 61

    5.5 What is the distribution of initiative support across the value chain? 62

    5.6 How are SMes supported through existing initiatives? 65

    5.7 are public health needs reflected in the current set of initiatives? 66

    6. conclusions & recommendations 69

    references 75

    appendices 83

  • r esistance to available antibiotics is one of the biggest threats to public health and ourhealthcare systems. Bacteria and infections that we cannot treat anymore, the medical procedures that cannot be performed anymore without life-threatening risks… the consequences of antibiotic resistance are beyond our imagination. that is why i have put antibiotic resistance high on the agenda of the Dutch Presidency and why i want to continue to call for action in other international forums.

    i believe in a one Health approach to this complex problem. it is a challenge we can only tackle by joining forces with multiple disciplines, by different solutions and new ideas. in the Netherlands we believe that working together in a one Health approach is crucial. this means closer collaboration between the human and veterinary side and between the different research instruments that we have. in February this year, the Netherlands organisation for Health research and Development launched a new €16 million research programme on antibiotic resistance, based on the one Health approach.

    one important solution set is the development of new antibiotics that are, ideally, less sensitive to resistance, alternative treatment and prevention options such as vaccines, and rapid diagnostics to target therapies. Scientists from different research areas, from academia and industry, from different countries, already work together in various research initiatives to develop these new ways to combat bacterial infections. it is important that they keep working t

Recommended

View more >